IMCD Spain expands its Pharmaceuticals presence with the acquisition of Cobapharma

IMCD Spain expands its Pharmaceuticals presence with the acquisition of Cobapharma

Written by Customer Service on . Posted in Mergers And Acquisitions.

Photo_IMCD Spain expands its Pharmaceuticals presence with the acquisition of Cobapharma

IMCD Spain expands its Pharmaceuticals presence with the acquisition of Cobapharma
Photographed from left to right:•Cristina Marti, Director API Sales and Strategy, IMCD Group•Gianluca Galimberti, General Manager, Cobapharma•Tess Hendriks, Legal Counsel M&A, IMCD Group•Fenna van Zanten, Director M&A, IMCD Group•Jose Alcover, Managing Director, IMCD Iberia & Maghreb

ROTTERDAM, The Netherlands 24 April 2024 – IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, today announces that IMCD Spain has signed an agreement to acquire 100% of the shares in Cobapharma, S.L.U, a European distributor in the pharmaceutical and nutraceutical industry.

Established in 2011 and headquartered in Barcelona, Spain, Cobapharma provides an extensive portfolio of Active Pharmaceutical Ingredients (APIs) as well as nutraceutical ingredients. With 20 employees, Cobapharma represents leading suppliers and generated a revenue of approximately EUR 19 million in the financial year that ended December 31, 2023.

‘Cobapharma is a rapidly growing distributor in the pharmaceutical and nutraceutical industry. Their esteemed reputation for providing high-quality APIs and nutraceutical ingredients perfectly complements our existing portfolio. The alignment of our business models will enhance our ability to serve our customers and partners’ comments John Robinson, Business Group Director IMCD Pharmaceuticals.

‘We are excited to join IMCD. This acquisition opens new opportunities for Cobapharma to expand its offerings and reach a broader customer base. We look forward to leveraging IMCD’s expertise and network to accelerate our growth and value creation to our customers’, says Gianluca Galimberti, General Manager Cobapharma.

The closing of the transaction is subject to customary (regulatory) closing conditions and is expected to take place in the second quarter of 2024.

Attached, the press release in PDF format, the main visual and photo caption.

Attachments

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.